Bluebird Bio to present new and updated data from gene therapy programs at ASH

bluebird bio announced that new long-term efficacy, safety and health-related quality of life follow-up data from its lentiviral vector gene therapy programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia who require regular red blood cell transfusions will be presented at the 65th American Society of Hematology, or ASH, Annual Meeting and Exposition that will take place December 9-12. bluebird bio will present updated follow-up data for lovotibeglogene autotemcel, or lovo-cel, in patients from the HBG-206 Group C and HGB-210 studies with sickle cell disease followed for up to 60 months, demonstrating sustained hemoglobin AT87Q production and near-complete resolution of vaso-occlusive events and severe VOEs, as well as sustained improvements in HRQoL. lovo-cel treatment regimen largely reflects known side effects of hematopoietic stem cell collection and busulfan conditioning regimen and underlying sickle cell disease. “The bluebird bio data to be presented at ASH 2023 underscore the maturity of LVV gene therapies for hemoglobinopathies, with up to 9 years of follow-up data in transfusion-dependent beta-thalassemia and 5 years of follow-up in sickle cell disease. The robustness of this dataset is unparalleled, giving us continued confidence that the transformational impact these therapies may have for patients is sustained over time. We especially look forward to the first ever presentation of data from our long-term follow-up study of lovo-cel, the most deeply studied gene therapy in development for sickle cell disease,” said Richard Colvin, M.D., Ph.D., Chief Medical Officer, bluebird bio.